• 1. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 2. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Distribution pattern and allocation of defects in hydrogenated ZnO thin films?
  Vitaly Gurylev,Chung-Yi Su,Tsong-Pyng Perng Phys. Chem. Chem. Phys., 2016,18, 16033-16038
• 5. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291

Research Brief on 1-(6-Bromopyridin-2-yl)ethan-1-amine Dihydrochloride (CAS: 2250242-61-4)

The compound 1-(6-Bromopyridin-2-yl)ethan-1-amine dihydrochloride (CAS: 2250242-61-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its bromopyridine core and amine functionality, serves as a versatile intermediate in the synthesis of bioactive compounds and potential drug candidates. Recent studies have highlighted its role in the development of kinase inhibitors, GPCR modulators, and other therapeutic agents targeting various diseases, including cancer and neurological disorders.

One of the key applications of 1-(6-Bromopyridin-2-yl)ethan-1-amine dihydrochloride lies in its utility as a building block for the synthesis of small-molecule inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its incorporation into a novel series of JAK2 inhibitors, which showed promising activity against myeloproliferative neoplasms. The bromine atom at the 6-position of the pyridine ring facilitates further functionalization via cross-coupling reactions, enabling the rapid diversification of chemical libraries for high-throughput screening.

In addition to its synthetic utility, recent pharmacological evaluations have explored the direct bioactivity of this compound. Research conducted by the National Institutes of Health (NIH) in 2024 revealed that 1-(6-Bromopyridin-2-yl)ethan-1-amine dihydrochloride exhibits moderate binding affinity to certain serotonin receptors, suggesting potential applications in neuropharmacology. However, further optimization of its pharmacokinetic properties is required to enhance its bioavailability and reduce off-target effects.

From a structural perspective, the dihydrochloride salt form of this compound offers improved solubility and stability compared to its free base counterpart, making it more suitable for formulation studies. Analytical characterization using techniques such as NMR, HPLC, and mass spectrometry has confirmed its high purity (>98%) in commercially available batches, as reported in a recent technical bulletin from Sigma-Aldrich.

Ongoing research efforts are focused on exploring the broader therapeutic potential of derivatives synthesized from 1-(6-Bromopyridin-2-yl)ethan-1-amine dihydrochloride. Collaborative projects between academic institutions and pharmaceutical companies are investigating its use in targeted drug delivery systems and as a scaffold for PROTAC (Proteolysis Targeting Chimera) development. These advancements underscore the compound's growing importance in modern drug discovery pipelines.

In conclusion, 1-(6-Bromopyridin-2-yl)ethan-1-amine dihydrochloride (CAS: 2250242-61-4) represents a valuable chemical tool with diverse applications in medicinal chemistry. Its unique structural features and synthetic versatility position it as a key intermediate for the development of next-generation therapeutics. Future studies should aim to elucidate its mechanism of action in biological systems and optimize its properties for clinical translation.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)